Zafgen Optimistic, But No Clear Path For Beloranib
This article was originally published in Scrip
You may also be interested in...
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.